Announcement of Termination of Co-Development and Exclusive Marketing
2022-11-09
基因疗法合作
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has decided jointly with Takara Bio Inc, (Takara Bio) to terminate agreements on co-development and exclusive marketing of NY-ESO-1・siTCR® gene therapy product (development code: TBI-1301).
Otsuka and Takara Bio have been jointly developing NY-ESO-1・siTCR® gene therapy for synovial sarcoma in Japan and preparing for the submission for manufacturing and marketing approval. However after comprehensive discussions between the two companies on policies and strategies related to this product, Otsuka and Takara Bio have agreed to terminate this agreement. This decision is not due to any efficacy or safety issues of the product.
Under this termination, Takara Bio regains technical, intellectual property and other rights granted by Takara Bio to Otsuka. In addition, in the future Takara Bio will not receive lump-sum payments upon achievement of milestones under this agreement or receive any sales proceeds for clinical trial product sales.
News releases below on original agreements with Takara Bio
Otsuka enters agreement with Takara Bio for co-development and sales rights in Japan to NY-ESO-1 siTCR and CD19 CAR gene therapies
https://www.otsuka.co.jp/en/company/newsreleases/2018/20180409_1.html
Designation Description Change of NY-ESO-1・siTCR gene therapy product under "SAKIGAKE Designation System"
https://www.otsuka.co.jp/en/company/newsreleases/2019/20190214_1.html
Clinical program for NY-ESO-1/siTCR gene therapy candidate receives designation in Japan as Orphan Regenerative Medicine
https://www.otsuka.co.jp/en/company/newsreleases/2020/20200624_1.html
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。